Mary E. DiLorenzo, MSN, RN-C, NP-C

As clinical providers, the ability to meet the science of medicine with its physical, emotional, spiritual, and financial impact it has on patients is often unintentionally overlooked or, at the very least, minimized during the active treatment phase of care; therefore, the purpose and potential benefits that result from integrating palliative care early on in the process is missed.

Our immune system’s successful detection and destruction of abnormal cells is the hallmark of our body’s ability to either stop a malignancy from occurring or halt it once it has begun.

At a recent meeting, some of the most preeminent physicians and researchers shed light on the all-too-familiar and intricate topic of chronic graft versus host disease (cGVHD) in the allogeneic hematopoietic-cell transplant (HCT) patient population.